Business / Finance

RSS

Duke, LifePoint enter joint venture to improve healthcare delivery for North Carolina community hospitals

Duke University Health System, Inc. and LifePoint Hospitals® have formed DLP Healthcare, LLC (Duke/LifePoint), a joint venture designed to strengthen and improve healthcare delivery throughout North Carolina and the surrounding regions by creating flexible affiliation options for community hospitals.

1 Feb 2011

Quest Diagnostics to repurchase 15.4M shares from GSK affiliate

Quest Diagnostics Incorporated today announced that it had agreed to repurchase at a negotiated price 15.4 million shares of its common stock from its largest shareholder, an affiliate of GlaxoSmithKline plc (GSK). Subsequent to the transaction, GSK will no longer hold any shares of common stock of Quest Diagnostics.

From Quest Diagnostics 1 Feb 2011

Valeant announces binding agreement to acquire PharmaSwiss for euro 350 million

Valeant Pharmaceuticals International, Inc. and PharmaSwiss S.A. announced today that they have signed a binding agreement for Valeant to acquire PharmaSwiss, a privately-owned branded generics and over-the-counter pharmaceutical company based in Zug, Switzerland for euro 350 million.

1 Feb 2011

Parker Tennessee accepts to purchase common stock of King Pharmaceuticals at $14.25 per share

Pfizer Inc. today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. at a purchase price of $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes.

1 Feb 2011

Encision reports gross profit margin increase in third quarter of fiscal year 2011

Encision, a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported profitable financial results for its third fiscal quarter ended December 31, 2010.

31 Jan 2011

Alexion announces acquisition of Taligen Therapeutics

Alexion Pharmaceuticals, announced that it has acquired Taligen Therapeutics, a privately held development-stage biotechnology company based in Cambridge, Mass.

31 Jan 2011

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that a binding subscription agreement has been executed in relation to share placement with Jiangsu Aosaikang Pharmaceutical Co., Ltd. (“ASK”). The proposed placement is for the issue of 14,334,080 LCT shares at A$0.12 per share, to raise A$1.72m. This represents a 5% equity stake in LCT, the funds to be received by LCT from ASK not later than 4 March 2011.

31 Jan 2011

Caraco generates $40.4 million and $268.2 million in third quarter, first nine months of Fiscal Year 2011

Caraco Pharmaceutical Laboratories, Ltd. generated net sales of $40.4 million and $268.2 million in the third quarter and first nine months of its Fiscal Year 2011, respectively, as compared to $52.0 million and $178.4 million, respectively, for the corresponding periods of our previous fiscal year ended December 31, 2009.

30 Jan 2011

Capital Pro-Égaux shares to continue on NEX

Capital Pro-Égaux Inc. announces that trading in its shares will resume on January 28, 2011 on NEX, a new and separate board of the TSX Venture Exchange.

29 Jan 2011

Angiotech commences CCAA proceedings to implement pre-packaged financial restructuring

Angiotech Pharmaceuticals, Inc. today announced that, further to its news release issued earlier today, the Company and certain of its subsidiaries have voluntarily commenced proceedings under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction, having obtained an Initial Order from the Supreme Court of British Columbia today.

29 Jan 2011

National Mentor Holdings prices 12.50% senior notes due 2018

National Mentor Holdings, announced today that it has priced an offering of $250 million in aggregate principal amount of 12.50% senior notes due 2018 through a private offering that is exempt from registration under the Securities Act of 1933, as amended.

29 Jan 2011

European Commission grants approval for Johnson & Johnson's proposed acquisition of Crucell

Johnson & Johnson and Crucell today announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell.

29 Jan 2011

Angiotech to continue implementation of previously announced recapitalization transaction under CCAA

Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.

29 Jan 2011

Viral Genetics enters binding Release and Settlement Agreement with T&T

Viral Genetics, and its President, Haig Keledjian, have entered into a binding Release and Settlement Agreement with Timothy and Thomas LLC and its principals that was approved by the court.

29 Jan 2011

GE Capital provides capital to XDx to help increase commercialization of AlloMap molecular diagnostic test

GE Capital, Healthcare Financial Services announced today that it has provided, as sole lender, a $12.5 million senior secured multi-draw term loan facility to XDx, Inc. The financing provides XDx with working capital to expand the commercialization of its FDA-cleared, innovative, noninvasive AlloMap molecular diagnostic test and pursue the development of other gene expression-based tests for autoimmune diseases including lupus.

29 Jan 2011

PHM announces financial results for quarter and year ended September 30, 2010

Patient Home Monitoring, a company focused on in-home cardiology healthcare services, today announced financial results for the quarter and year ended September 30, 2010.

29 Jan 2011

Bionovo prices public offering of common stock at $1.30 per share

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced the pricing of its previously announced underwritten public offering, to sell up to 30,031,200 units at a price per unit of $1.00 for aggregate gross proceeds of approximately $30 million.

29 Jan 2011

Adeona to sell 2.85 million common stock at $1.40 per share

Adeona Pharmaceuticals, a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sale of approximately 2.85 million shares of its common stock at $1.40 per share to two new institutional investors in a registered direct offering for $4 million in gross proceeds.

29 Jan 2011

Covalon Technologies' annual revenue up 54%

Covalon Technologies Ltd., an advanced medical technologies company, today announced the following financial results for its year ended September 30, 2010

29 Jan 2011

Athersys enters definitive agreements to sell common stock, warrants

Athersys, announced today that it has entered into definitive agreements with certain investors to sell 4,366,667 shares of its common stock and warrants to purchase up to an additional 1,310,000 shares of common stock in a registered direct offering for gross proceeds of approximately $13.1 million, before deducting fees and offering expenses.

29 Jan 2011

Business / Finance

Duke, LifePoint enter joint venture to improve healthcare delivery for North Carolina community hospitals

Quest Diagnostics to repurchase 15.4M shares from GSK affiliate

Valeant announces binding agreement to acquire PharmaSwiss for euro 350 million

Parker Tennessee accepts to purchase common stock of King Pharmaceuticals at $14.25 per share

Encision reports gross profit margin increase in third quarter of fiscal year 2011

Alexion announces acquisition of Taligen Therapeutics

Jiangsu Aosaikang Pharmaceutical to take 5% equity position in Living Cell Technologies

Caraco generates $40.4 million and $268.2 million in third quarter, first nine months of Fiscal Year 2011

Capital Pro-Égaux shares to continue on NEX

Angiotech commences CCAA proceedings to implement pre-packaged financial restructuring

National Mentor Holdings prices 12.50% senior notes due 2018

European Commission grants approval for Johnson & Johnson's proposed acquisition of Crucell

Angiotech to continue implementation of previously announced recapitalization transaction under CCAA

Viral Genetics enters binding Release and Settlement Agreement with T&T

GE Capital provides capital to XDx to help increase commercialization of AlloMap molecular diagnostic test

PHM announces financial results for quarter and year ended September 30, 2010

Bionovo prices public offering of common stock at $1.30 per share

Adeona to sell 2.85 million common stock at $1.40 per share

Covalon Technologies' annual revenue up 54%

Athersys enters definitive agreements to sell common stock, warrants

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News